Skip to Content

Press Releases

Press Releases

Oct 12 2015
Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms
JERUSALEM, ISRAEL--(Marketwired - Oct 12, 2015) -  Intec Pharma Ltd . (NASDAQ: NTEC) (TASE: INTC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced results of the food effect study of the Phase 3
Sep 17 2015
Intec Pharma Ltd. Announces Partial Exercise of Underwriters Option to Purchase Additional Ordinary Shares
JERUSALEM, ISRAEL--(Marketwired - Sep 17, 2015) -  Intec Pharma Ltd . (the "Company") (NASDAQ: NTEC) (TASE: INTC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that the underwriters of its
Displaying 101 - 102 of 102